Matrilin-3 Induction of IL-1 receptor antagonist Is required for up-regulating collagen II and aggrecan and down-regulating ADAMTS-5 gene expression
1 Department of Orthopedics; Warren Alpert Medical School of Brown University, Providence RI 02903, USA
2 Research Division, The Hospital for Special Surgery, and Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY 10021, USA
Arthritis Research & Therapy 2012, 14:R197 doi:10.1186/ar4033Published: 11 September 2012
Additional file 1:
Kinetics of matrilin-3 (MATN3)-induced IL-1Ra gene expression in human chondrocytes. A figure showing MATN3 stimulation of IL-1Ra gene upregulation by C28/I2 cells and primary human chondrocytes (PHCs) in the absence (A, C) and presence of IL-1β (B, D). Cells were treated with 0, 100 or 200 ng/ml of recombinant human MATN3 protein. IL-1β was used at a concentration of 5.0 ng/ml. *P ≤ 0.05 for statistically significant differences relative to the 0 ng/ml treatment group, for each respective time point. Individual experiments were done in biological triplicate.
Format: JPEG Size: 57KB Download file
Additional file 2:
Matrilin-3 (MATN3) stimulates type II collagen (COL2A1) mRNA levels for at least 24 hours in human chondrocytes. A figure showing that MATN3 induces COL2A1 mRNA levels in C28/I2 cells (A) and primary human chondrocytes (PHCs) (B) after 24 hours treatment. Recombinant human (rh) MATN3 protein is used at 200 ng/ml and rh IL-1β protein treatment is used at 5.0 ng/ml. *P ≤ 0.05 for statistically significant differences from the untreated control group; #P ≤ 0.05 for statistically significant differences from the IL-1β only treated group. Data are representative of three individual experiments.
Format: JPEG Size: 26KB Download file